newsfilter
← Latest News
Business Wire·

Frequency Therapeutics Announces New FX-322 Results Showing That Additional Study Participants Gain Hearing Improvements at Later Time Points

In Follow-Up to Phase 1b Learning Study (FX-322-111), Some Subjects with Sensorineural Hearing Loss Show Increased Speech Perception Up to Twelve Months After Dosing Frequency Therapeutics, Inc. (NASDAQ:FREQ), a clinical-stage regenerative medicine c